URB602
N-aryl carbamate used in 2005 as a MAGL inhibitor; low potency (IC50 25 to 223 µM depending on the assay) and disputed selectivity.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₉H₂₁NO₂
CAS 565460-15-3
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 295.40 g/mol
Updated on
In plain terms
URB602 is a laboratory molecule that weakly slows the enzyme responsible for destroying 2-AG, a messenger the body makes itself. In 2005, a study in rats used it to show that stress releases the body's own cannabinoids in one brain region. Later work showed that its action on the enzyme is weak and that it also acts on the breakdown of anandamide.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to URB602: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of URB602.
MAGLMAGL found in 5 regions of the body
Map sources
- Takahata K et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with (18)F-T-401. Eur J Nucl Med Mol Imaging, 2022 (new tab)
- Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 2011 (new tab)
- Spoto B et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie, 2006 (new tab)
- Human Protein Atlas. MGLL expression summary (new tab)
Cited values
- MAGLInhibitorIC50 = 25 µM · rat10 out of 100
Vandevoorde et al., Br J Pharmacol 2007: lack of selectivity of URB602 for 2-oleoylglycerol hydrolysis over that of anandamide (new tab) · hydrolysis of [3H]-2-oleoylglycerol, cytosolic fractions of rat brain (25 µM); non-selective: anandamide hydrolysis inhibited at 17 µM
- MAGL (enzyme recombinante)InhibitorIC50 = 223 µM · rat4 out of 100
King et al., Chem Biol 2007: URB602 inhibits MAGL (IC50 223 µM on the recombinant rat enzyme) and blocks 2-AG degradation in brain slices (new tab) · recombinant rat MGL, partially reversible non-competitive inhibition (223 ± 63 µM)
Pharmacology
URB602 is an N-aryl carbamate that served as the first tool for varying 2-AG in the brain. In 2005, Hohmann and colleagues showed that stress-induced analgesia, in its opioid-independent form, is mediated by the release of endogenous cannabinoids: stress causes the rapid formation of 2-AG and anandamide in the periaqueductal grey matter, blocking CB1 receptors in that region prevents non-opioid analgesia, and a MAGL inhibitor injected locally selectively raised 2-AG and enhanced this analgesia in a CB1-dependent manner (Hohmann et al. 2005; King et al. 2007 identify this inhibitor as URB602, in rats). The same year, Makara et al. used it in the hippocampus, where it prolonged 2-AG-dependent retrograde signalling (as described by King et al. 2007). Its biochemical characterisation has remained disappointing: IC50 values range from 25 µM to 223 µM depending on the assay, inhibition of anandamide hydrolysis is of the same order (17 µM), and King et al. describe a partially reversible mechanism (Vandevoorde et al. 2007; King et al. 2007). It remains a tool used at high concentration, whose results must be interpreted with this limit in mind; no human data were found in the sources consulted.
Key sources.
- Hohmann et al., Nature 2005: an endocannabinoid mechanism for stress-induced analgesia (new tab)PMID 15973410
- Makara et al., Nat Neurosci 2005: selective inhibition of 2-AG hydrolysis enhances endocannabinoid signalling in the hippocampus (new tab)PMID 16116451
- King et al., Chem Biol 2007: URB602 inhibits MAGL (IC50 223 µM on the recombinant rat enzyme) and blocks 2-AG degradation in brain slices (new tab)PMID 18096504
- Vandevoorde et al., Br J Pharmacol 2007: lack of selectivity of URB602 for 2-oleoylglycerol hydrolysis over that of anandamide (new tab)PMID 17143303
- PubChem, URB602, CID 10979337 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound (an N-aryl carbamate), with no known natural occurrence. It is used as an experimental pharmacology reagent; no clinical development was found in the sources consulted.
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is an N-aryl carbamate, the cyclohexyl ester of biphenyl-3-ylcarbamic acid (King et al. 2007).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: URB602 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a biphenyl carbamate) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Hohmann et al., Nature 2005: an endocannabinoid mechanism for stress-induced analgesia (new tab)PMID 15973410
- Makara et al., Nat Neurosci 2005: selective inhibition of 2-AG hydrolysis enhances endocannabinoid signalling in the hippocampus (new tab)PMID 16116451
- King et al., Chem Biol 2007: URB602 inhibits MAGL (IC50 223 µM on the recombinant rat enzyme) and blocks 2-AG degradation in brain slices (new tab)PMID 18096504
- Vandevoorde et al., Br J Pharmacol 2007: lack of selectivity of URB602 for 2-oleoylglycerol hydrolysis over that of anandamide (new tab)PMID 17143303
- PubChem, URB602, CID 10979337 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- cyclohexyl N-(3-phenylphenyl)carbamate
- Other names
- URB 602 · URB-602
Identifiers
- Formula
- C₁₉H₂₁NO₂
- CAS
- 565460-15-3
- PubChem CID
- 10979337(new tab)
- InChIKey
- HHVUFQYJOSFTEH-UHFFFAOYSA-N
- SMILES
- C1CCC(CC1)
OC(= O) NC2= CC= CC(= C2) C3= CC= CC= C3
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.